HOME | 마이페이지
마이페이지
초록접수목록
LXRβ/NF-κB axis alters the state of CD8+ T cells in tumours.
Abstract No. : 48

Category

Engineered T cell therapy (e.g., CAR/TCR-T)
Liver X Receptors β (LXRβ) are pivotal transcription factors that regulate lipid metabolism in immune systems. LXRβ is known to influence the fitness and functionality of T cells; however, its impact on T cells within the tumor microenvironment remains poorly understood. Additionally, LXRβ inhibits NF-κB target genes, yet the interplay between LXRβ and NF-κB in CD8+ T cells within tumors has not been fully elucidated. This study aims to uncover the roles of LXRβ and NF-κB in modulating CD8+ T cell function in tumor microenvironments. We used CRISPR/Cas9 and retroviral transduction to modify CAR T cells, assessed their cytotoxicity in vitro, analyzed exhaustion by flow cytometry, and studied their anti-tumor effects in a mouse model. In this study, we observed changes in the expression levels of TCF1 and Ki-67 in LXRβ-engineered CAR T cells. Notably, LXRβ expression was found to regulate the secretion of cytokines IFNγ and TNFα. Furthermore, modulating NF-κB signaling altered the cytotoxic responses of both LXRβ-overexpressing (OE) and knockout (KO) CAR T cells, highlighting its potential impact on their functionality. Based on these findings, we propose that the interaction between LXRβ and NF-κB signaling plays a crucial role in modulating CAR T cell functionality. These results suggest that genetic targeting of LXRβ/NF-κB pathways could open new avenues for enhancing tumor immunotherapies.
#Chimeric Antigen Receptor T-cell (CART)
#LXRβ
#NF-κB
#Cancer Immunotherapy
면역세포유전자치료학회 홈페이지에 오신 것을 환영합니다.
필요한 자료를 검색해 보세요 !
KAICET
한국면역세포유전자치료학회